MX2022007961A - Nuevos anticuerpos anti-fgfr2b. - Google Patents
Nuevos anticuerpos anti-fgfr2b.Info
- Publication number
- MX2022007961A MX2022007961A MX2022007961A MX2022007961A MX2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A MX 2022007961 A MX2022007961 A MX 2022007961A
- Authority
- MX
- Mexico
- Prior art keywords
- novel anti
- fgfr2b
- antibodies
- fgfr2b antibodies
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019127904 | 2019-12-24 | ||
| PCT/CN2020/138659 WO2021129672A1 (en) | 2019-12-24 | 2020-12-23 | Novel anti-fgfr2b antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007961A true MX2022007961A (es) | 2022-07-12 |
Family
ID=76575671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007961A MX2022007961A (es) | 2019-12-24 | 2020-12-23 | Nuevos anticuerpos anti-fgfr2b. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230052680A1 (enExample) |
| EP (1) | EP4081547A4 (enExample) |
| JP (1) | JP7692419B2 (enExample) |
| KR (1) | KR20220119144A (enExample) |
| CN (1) | CN114846029A (enExample) |
| AR (1) | AR120886A1 (enExample) |
| AU (1) | AU2020412088A1 (enExample) |
| CA (1) | CA3160812A1 (enExample) |
| MX (1) | MX2022007961A (enExample) |
| TW (1) | TWI861326B (enExample) |
| WO (1) | WO2021129672A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR120884A1 (es) * | 2019-12-24 | 2022-03-23 | Dizal Jiangsu Pharmaceutical Co Ltd | Anticuerpos anti-fgfr2b |
| AU2023243773A1 (en) * | 2022-03-28 | 2024-10-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Novel anti-fgfr2 antibodies. |
| WO2024199362A1 (en) * | 2023-03-31 | 2024-10-03 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Novel anti-FGFR2 antibodies |
| CN118852431A (zh) * | 2023-04-28 | 2024-10-29 | 武汉人福创新药物研发中心有限公司 | 抗FGFR2b单抗 |
| CN118994393A (zh) * | 2023-05-19 | 2024-11-22 | 广东东阳光药业股份有限公司 | 一种抗fgfr2抗体及其应用 |
| TW202540177A (zh) * | 2023-11-14 | 2025-10-16 | 大陸商蘇州創勝醫藥集團有限公司 | 抗－ＦＧＦＲ２ｂ免疫偶聯物及其於治療癌症的用途 |
| WO2025130905A1 (zh) * | 2023-12-18 | 2025-06-26 | 山东先声生物制药有限公司 | 抗FGFR2b抗体-药物缀合物及其应用 |
| WO2025146131A1 (en) * | 2024-01-05 | 2025-07-10 | Beigene, Ltd. | ANTI-FGFR2b ANTIBODIES, CONJUGATES AND METHODS OF USE |
| CN120424212A (zh) * | 2024-01-26 | 2025-08-05 | 上海安领科生物医药有限公司 | 抗FGFR2b抗体及抗体药物偶联物 |
| CN118772279B (zh) * | 2024-06-28 | 2025-03-25 | 北京普利米特生物科技有限公司 | 抗FGFR2b抗体或其抗原结合片段及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7357928B2 (en) * | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| DK3290052T3 (da) * | 2008-11-07 | 2020-02-03 | Galaxy Biotech Llc | Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 |
| US10233249B2 (en) * | 2013-03-19 | 2019-03-19 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| MX374785B (es) * | 2013-08-01 | 2025-03-06 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados. |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| SG10201913538VA (en) | 2015-11-23 | 2020-02-27 | Five Prime Therapeutics Inc | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
| DK3624837T3 (da) * | 2017-05-16 | 2025-09-29 | Five Prime Therapeutics Inc | Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling |
-
2020
- 2020-12-23 CN CN202080090068.7A patent/CN114846029A/zh active Pending
- 2020-12-23 WO PCT/CN2020/138659 patent/WO2021129672A1/en not_active Ceased
- 2020-12-23 JP JP2022539176A patent/JP7692419B2/ja active Active
- 2020-12-23 KR KR1020227025532A patent/KR20220119144A/ko active Pending
- 2020-12-23 MX MX2022007961A patent/MX2022007961A/es unknown
- 2020-12-23 CA CA3160812A patent/CA3160812A1/en active Pending
- 2020-12-23 EP EP20904516.0A patent/EP4081547A4/en active Pending
- 2020-12-23 AU AU2020412088A patent/AU2020412088A1/en active Pending
- 2020-12-23 US US17/788,733 patent/US20230052680A1/en active Pending
- 2020-12-23 AR ARP200103630A patent/AR120886A1/es unknown
- 2020-12-24 TW TW109145975A patent/TWI861326B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4081547A1 (en) | 2022-11-02 |
| WO2021129672A1 (en) | 2021-07-01 |
| US20230052680A1 (en) | 2023-02-16 |
| TW202136311A (zh) | 2021-10-01 |
| EP4081547A4 (en) | 2024-02-21 |
| TWI861326B (zh) | 2024-11-11 |
| JP2023508174A (ja) | 2023-03-01 |
| CN114846029A (zh) | 2022-08-02 |
| KR20220119144A (ko) | 2022-08-26 |
| CA3160812A1 (en) | 2021-07-01 |
| AU2020412088A1 (en) | 2022-06-23 |
| AR120886A1 (es) | 2022-03-30 |
| JP7692419B2 (ja) | 2025-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3149406A1 (en) | Novel anti-cldn18.2 antibodies | |
| MX2022007959A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| MX2024007966A (es) | Anticuerpos anti-tslp novedosos. | |
| MX2025009320A (es) | Anticuerpos anti-cd19 novedosos | |
| MX2022007960A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| WO2020039321A3 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| PH12020551716A1 (en) | Anti-ror antibody constructs | |
| WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| MX2023008423A (es) | Anticuerpos anti-gremlin1 novedosos. | |
| PH12020550078A1 (en) | Novel anti-cd3epsilon antibodies | |
| IL285651A (en) | Anti-trem2 antibodies, preparations containing them and their uses | |
| WO2017106684A3 (en) | Antibodies specifically binding hla-dr and their uses | |
| WO2018170351A8 (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2019007021A (es) | Anticuerpos il-11ra. | |
| ZA202106602B (en) | Claudin 6 antibodies and uses thereof | |
| GB201910389D0 (en) | Novel compounds, methods for their manufacture, and uses thereof | |
| WO2017214458A3 (en) | Anti-cd98 antibodies and antibody drug conjugates | |
| WO2017214462A3 (en) | Anti-cd98 antibodies and antibody drug conjugates | |
| AR120886A1 (es) | Anticuerpos anti-fgfr2b | |
| WO2018069871A3 (en) | Anti-kras binding proteins | |
| AU2019321490A8 (en) | Ox40-binding polypeptides and uses thereof | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| EP4273165A3 (en) | Interferon beta antibodies and uses thereof | |
| WO2020260898A3 (en) | Novel cancer antigens and methods |